CRESCENT BIOPHARMA, INC.

Regulatory Filings • May 18, 2016

8-K 1 glyc-20160517x8k.htm 8-K HTML document created with Merrill Bridge 6.1.177.0 Created on: 5/18/2016 2:34:27 PM glyc_Current_Folio_8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2016

GLYCOMIMETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-36177	06-1686563
(Commission File No.)	(IRS Employer Identification No.)

9708 Medical Center Drive

Rockville, MD 20850

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (240) 243-1201

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 17, 2016, GlycoMimetics, Inc. (the “ Company ”) held its 2016 annual meeting of stockholders (the “ Annual Meeting ”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2016. Of the 19,330,396 shares outstanding as of the record date, 16,845,577 shares, or 87.1%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1 : Election of three nominees to serve as directors until the 2019 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

Name	Votes For	Votes Withheld
John J. Baldwin, Ph.D.	13,642,749	604,666
M. James Barrett, Ph.D.	13,616,645	630,770
John L. Magnani, Ph.D.	13,668,949	578,466

Broker Non-Votes: 2,598,162.

All nominees were elected.

Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2016. The votes were cast as follows:

	Votes For	Votes Against	Abstained
Ratification of appointment of Ernst & Young	16,834,072	11,409	96

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GLYCOMIMETICS, INC.
By:	/s/ Brian M. Hahn
Date: May 18, 2016	Brian M. Hahn
	Chief Financial Officer

3